. .. Facteurs-de-risque,

. .. Âge,

. .. Antécédents-familiaux-de-mm,

.. .. Antécédents-de-mgus-ou-de-plasmocytome-solitaire,

.. .. Facteurs-de-risques-possibles,

. .. Conclusion,

, Réflexion sur la stratégie de développement et d'enregistrement internationale, p.49

U. Nouveau and .. .. Dans-le-myélome-multiple, 50 3.2.1 Soutient et opportunités réglementaires en amont de l'enregistrement

.. .. Stratégie-d'enregistrement-internationale,

. .. Conclusion,

.. .. Conclusion-générale,

. .. Liste-des-tableaux, , vol.87

. .. Bibliographie,

. Bibliographie,

, InfoCancer-ARCAGY-GINECO-Localisations-Cancers du sang-Hémopathies-Leucémie Myéloïde

. Disponible,

. Disponible,

-. Infocancer, Cancers du sang-Hémopathies-Myélome Multiple (MM)-Maladie-Les lymphocytes, 2017.

. Qu, est-ce que le myélome multiple ?-Société canadienne du cancer

. Disponible,

. Biochimie-constantes_biologiques_adultes_2009, , 2017.

. Comprendre-le-myélome-multiple, A. Inca, and . Le-soutien-financier-de-la-ligue-nationale-contre-le-cancer, , 2015.

-. Infocancer, Cancers du sang-Hémopathies-Myélome Multiple (MM), 2017.

. Disponible,

S. V. Rajkumar, S. M. Kumar, and . Myeloma, Diagnosis and Treatment, Mayo Clin Proc, vol.91, issue.1, pp.101-119, 2016.

. Poly-hémato,

. Disponible,

. Poly-hémato,

. Disponible,

, Haute Autorité de Santé-ALD n° 30-Myélome multiple. Guide patient-affection longue durée-La prise

. Disponible,

, Haute Autorité de Santé-ALD n° 30-Myélome multiple. Guide patient-affection longue durée-Tumeur

, Juillet, 2018.

. Disponible,

. Torimoto, Current therapeutic strategies for multiple myeloma, International Journal of Clinical Oncology. 2015, vol.20, issue.3, pp.423-430

, Heads of Medicines Agencies: MRI Product Index, 2018.

, European Medicines Agency-Find medicine-European public assessment reports

, Juillet, 2018.

. Disponible,

, Drugs Approved for Multiple Myeloma. National Cancer Institute

. Disponible,

, Multiple Myeloma: Treatment Options, Cancer.Net, 2018.

S. Stavric, How is patient care for multiple myeloma advancing? Expert Review of Hematology, vol.10, pp.551-561, 2017.

J. Ferlay, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, pp.1374-1403, 2013.

, Worldwide data | World Cancer Research Fund International

. Disponible,

. Globocan-|-online-analysis-map, , 2017.

U. K. Myeloma-incidence-statistics-|-cancer-research, , 2017.

, Orphanet | Prévalence des maladies rares par ordre alphabétique

. Disponible,

. Disponible,

A. Monnereau, Estimation nationale de l'incidence des cancers en France entre 1980 et 2012-Partie 2 : Hémopathies malignes, 2013.

L. Cancers-en-france and L. Données, , 2014.

. Disponible,

, Key Statistics for Multiple Myeloma, 2018.

|. Myeloma and . Sheets, , 2018.

. Disponible,

, Myeloma statistics | Cancer Australia, 2018.

. Disponible,

S. Ozaki, Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma, Blood Cancer Journal. 2015, vol.5

, HOME. Cancer information Service

. Disponible,

. Kim, Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study, American Journal of Hematology, vol.89, issue.7, pp.751-756, 2014.

, Facteurs de risque du MM-Société canadienne du cancer

. Disponible,

. Disponible,

. S. Kumar, Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study, Leukemia. 2012, vol.26, issue.1, pp.149-157

. S. Usmani, Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ?3

, Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or

, Double Refractory to a PI and an IMiD, Oncologist. 2016, vol.21, issue.11, pp.1355-1361

W. Y. Cheung, Difficult to swallow: issues affecting optimal adherence to oral anticancer agents, Am Soc Clin Oncol Educ Book, vol.2013, pp.265-270

A. H. Partridge, Adherence to therapy with oral antineoplastic agents, J Natl Cancer Inst, vol.94, pp.652-661, 2002.

S. Schneider, Interventions to promote adherence with oral agents, Semin Oncol Nurs, vol.27, pp.133-141, 2011.

M. Siegenthaler and W. Sietsema, Global Pharmaceutical and Biologics Regulatory Strategy. The Regulatory Affairs Professionnals Society, 2016.

, European Medicines Agency-Overview-Supporting SMEs, 2017.

. Disponible,

, European Medicines Agency-Research and development-PRIME: priority medicines

, European Medicines Agency-Factsheet: PRIME at a glance

. Disponible,

, European Medicines Agency-List of products granted eligibility to PRIME

, Juillet, 2018.

. Fda, Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics

, Novembre, 2017.

. Fda-cder/cber and B. Nda, Approval Reports-Breakthrough Therapy Approvals

F. Cber, NDA and BLA Approval Reports-Fast Track Approvals for Drugs

T. Gammie, Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. Plos one, 2015.

, European Medicines Agency-Orphan designation-Applying for orphan designation

. Disponible,

. Disponible,

, European Medicines Agency-Human medicines-Rare disease (orphan) designations

. Disponible,

. Disponible,

, FDA Orphan Drug Designation 101

, Orphan Drug Regulations, 2018.

. Ministry and . Health, Labour and Welfare. The Article 77-2 of the Pharmaceutical Affairs Law

. Ministry and . Health, Labour and Welfare: Pharmaceuticals and Medical Devices

. Swissmedic, HD-Guidance document Orphan Drug, 2017.

. Akhvgaaw0qfggrmaa&url=https%3a%2f%2fwww, , pp.2-2

. Swissmedic, Médicaments importants pour des maladies rares, 2018.

. Disponible,

, Federal Register of Legislation-Australian Government, 2017.

. Disponible,

, Australian Government Department of Health Therapeutic Goods. Orphan Drug Program Reforms, 2017.

, Australian Government Department of Health Therapeutic Goods. Orphan Drug Designation Eligibility Criteria, Therapeutic Goods Administration (TGA)

. Disponible,

, Australian Government Department of Health Therapeutic Goods. Orphan drug designation A step-by-step guide for prescription medicines, Therapeutic Goods Administration (TGA)

. Disponible,

, Australian Government Department of Health Therapeutic Goods. Orphan Drug Designation prior to 1, Therapeutic Goods Administration (TGA), 2017.

. Disponible,

, Addendum to ICH E11: clinical investigation of medicinal products in the pediatric population E11 (R1)

, EMA/973755/2011-European Medicines Agency decision, 2018.

. Disponible,

. Fda, Guidance for Industry How to Comply with the Pediatric Research Equity Act

. Fda, Adult-Related Conditions that qualify for a waiver because they rarely or never occur in pediatric, 2018.

, EU 10-Eudralex-VOLUME 10-Rules for governing medicinal products in the European Union

. Disponible,

. Disponible,

R. Abdrachitov, New Regulatory Landscape for clinical trials in Russia

, Septembre, 2017.

. Disponible,

, Regulation (EU) No 536/2014 of the European Parliament and of the council-Clinical Trial Regulation of

, Clinical Trials on Medicinal Products for Human Use, 2014.

F. Cber, Investigational New Drug (IND) Application

F. Cber, Pre-IND Consultation Program, 2017.

. Disponible,

. Fda, Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants

, European Medicines Agency-Research and development-Scientific advice and protocol assistance

. Disponible,

, European Medicines Agency-Scientific advice and protocol assistance-How to submit a scientific advice or protocol assistance request. Pre-submission meeting, 2017.

. Early-dialogues-eunethta, , 2017.

. Disponible,

, European Medicines Agency-Human regulatory-Marketing autorisation

. Disponible,

, European Medicines Agency-Marketing authorisation-Pre-authorisation guidance

, Juillet, 2018.

, The Drug Development Process-Step 4: FDA Drug Review

. Disponible,

C. Fda, New Drug Application (NDA)

. Disponible,

, Points to Be Considered by the Review Staff Involved in the Evaluation Process of New Drug (FINAL)

. Disponible,

, Reviews | Pharmaceuticals and Medical Devices Agency, 2018.

. Disponible,

S. Canada, Comment les médicaments sont examinés au Canada. Éducation et sensibilisation

. Swissmedic, HD-Guidance document. Authorisation human medicine under Art. 13 ATP

, Juillet, 2018.

, Australian Government Department of Health Therapeutic Goods. Prescription Medicines Registration Process, Therapeutic Goods Administration (TGA)

. Disponible,

, Medsafe's Evaluation and Approval Process, 2018.

. Disponible,

, Registraton of medicines in the eurasian economic union

, Juillet, 2018.

, SAHPRA-South African Health Products Regulatory Authority, 2018.

. Disponible,

, Department of health. Medicines and related substances Act

. Disponible,

. Anvisa, , 2018.

, Distribution and Marketing of Drugs in Brazil: Overview

. Disponible,